Skip to content

Physician-led care since 20194.9 on Google

Text (407) 233-4006Call

Not sure where to start? Answer a few questions about your symptoms in the 4-minute hormone quiz.

Take the quiz

Not near a clinic? Peptide therapy is available by telehealth in 27 states.Telehealth

Your care team

  • Dr. Joseph Clark, D.O.

    Dr. Joseph Clark, D.O.

    Chief Medical Officer

    Board certified in Emergency Medicine, with 20+ years in medicine.

  • Tomo Marjanovic

    Tomo Marjanovic

    Founder and CEO

    Former police officer awarded the Medal of Valor. IFAH Top 100 Healthcare Visionary.

4.9 on Google from 700+ reviews

Aspire Rejuvenation Clinic

Menu

Text or call us at (407) 233-4006. Mon to Fri, 9:30 AM to 6:00 PM.

Book a Consultation

Peptide Therapy  /  DSIP

DSIP

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuromodulator first isolated from rabbit brain tissue in 1977. It has been studied for its role in promoting delta-wave sleep patterns, modulating stress hormone responses, and supporting the body's natural circadian rhythm architecture.

ClassificationNonapeptide Neuromodulator
Sequence Length9 Amino Acids
Primary InterestSleep Regulation & Stress Adaptation
Research StatusClinical & Preclinical Research
Interested in DSIP?

Talk with an Aspire clinician about whether DSIP may be appropriate for your health goals.

Text Us Now
(407) 233-4006
What is DSIP?

Delta Sleep-Inducing Peptide - A Natural Sleep Neuromodulator

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nine amino acid neuropeptide originally isolated from the cerebral venous blood of rabbits during induced sleep by Schoenenberger and Monnier in 1977. It is found naturally in the human hypothalamus and pituitary gland, and has been identified in the bloodstream at varying concentrations that fluctuate with circadian rhythms. DSIP belongs to a class of endogenous sleep-regulatory substances that the body produces to help govern the sleep-wake cycle.

Research spanning several decades has examined DSIP's effects on sleep architecture, particularly its relationship with slow-wave (delta) sleep stages. Clinical studies, primarily conducted in European research centers, have investigated DSIP in patients with insomnia and disrupted sleep patterns. Additional research has explored its role in stress-hormone modulation, pain perception, and withdrawal symptom management. The peptide appears to function more as a sleep modulator than a sedative, meaning it may help normalize disrupted sleep patterns rather than forcing unconsciousness.

Aspire Rejuvenation offers DSIP through licensed 503A compounding pharmacies for patients whose sleep disruptions have been evaluated and for whom conventional approaches may not have provided adequate results. Our physicians assess sleep quality, stress markers, and hormone levels before determining if DSIP may be an appropriate component of a comprehensive sleep optimization strategy.

Lifestyle photography representing restful sleep recovery wellness - DSIP therapy at Aspire Rejuvenation
How It Works

Proposed Mechanism of Action

1
Hypothalamic Action
DSIP interacts with receptors in the hypothalamus, the brain's master sleep-wake regulator, where it may modulate the firing patterns of sleep-promoting neurons in the ventrolateral preoptic area.
2
Delta Wave Promotion
Research suggests DSIP promotes the transition into slow-wave (Stage 3) sleep characterized by delta brain wave activity, the deepest and most physically restorative phase of the sleep cycle.
3
Cortisol Modulation
Studies have found that DSIP may influence the hypothalamic-pituitary-adrenal (HPA) axis, helping to normalize cortisol rhythms that, when dysregulated, are a common contributor to sleep disruption.
4
Circadian Rhythm Support
DSIP's endogenous levels naturally fluctuate with circadian patterns. Exogenous administration has been studied for its potential to help re-establish disrupted circadian timing and sleep-wake regularity.

DSIP's mechanism of action is multifaceted and not fully elucidated, which is consistent with its role as a neuromodulatory peptide rather than a compound with a single receptor target. Research suggests it acts on several systems simultaneously. In the hypothalamus, DSIP appears to influence the sleep-promoting neurons of the ventrolateral preoptic area (VLPO) while modulating the activity of wake-promoting orexin neurons. Unlike benzodiazepines or other sedative-hypnotics, DSIP does not appear to suppress neural activity broadly - instead, it seems to shift the balance of sleep-wake neurocircuitry toward sleep-promoting states.

A significant body of research has focused on DSIP's interaction with the stress axis. Studies have demonstrated effects on ACTH and cortisol secretion patterns, suggesting DSIP may help normalize HPA axis activity in individuals experiencing stress-related sleep disruption. Additional research has identified interactions with serotonergic and GABAergic systems, both of which play established roles in sleep regulation. Some studies have also noted DSIP's ability to modulate LH release and interact with opioid systems, suggesting a broader neuroendocrine regulatory role beyond sleep alone.

Areas of Interest

What DSIP Is Being Explored For

These are the primary areas where DSIP has been studied or discussed in the context of peptide therapy. Research depth varies by area.

Sleep Quality & Architecture
Clinical studies have examined DSIP's effects on sleep onset latency, total sleep time, and the proportion of time spent in deep slow-wave sleep. Research suggests it may be particularly relevant for individuals with disrupted sleep architecture rather than total insomnia.
Stress-Related Sleep Disruption
DSIP's interaction with the HPA axis has made it a subject of research for stress-induced insomnia. Studies have explored whether its cortisol-modulating properties may help break the cycle of elevated stress hormones preventing restful sleep.
Circadian Rhythm Disruption
Research has investigated DSIP in the context of shift work, jet lag, and other circadian disruptions, examining whether exogenous DSIP administration can help re-establish normal sleep-wake timing.
Pain & Sleep Interaction
Given DSIP's observed interactions with opioid receptor systems, researchers have explored its role in the bidirectional relationship between chronic pain and sleep disruption, where poor sleep amplifies pain sensitivity and pain disrupts sleep.
Available at Aspire

How DSIP Is Offered

DSIP is available through Aspire in the following formulations, all compounded by licensed U.S. 503A pharmacies. Your clinician will recommend the appropriate form based on your goals and treatment plan.

Injectable (Subcutaneous)
Nasal Spray
Questions About DSIP?

Text our team anytime during business hours.
Monday through Friday, 9:30 AM - 6:00 PM.
We're here to help you understand your options.

Text Us Now — (407) 233-4006
The Aspire Approach

How Treatment Works

Peptide therapy at Aspire follows a clinician-guided process. DSIP is not available for self-prescribing or anonymous purchase.

1
Sleep & Stress Assessment
Your evaluation includes a detailed sleep history, stress assessment, relevant lab work including cortisol patterns, and a review of any prior interventions to provide complete context for your DSIP candidacy.
2
Physician Protocol Development
An Aspire physician analyzes your assessment results and determines whether DSIP may be appropriate as part of a broader sleep optimization approach that may include lifestyle modifications and complementary therapies.
3
Pharmacy Preparation & Guidance
Your DSIP is prepared by a licensed 503A compounding pharmacy. Our clinical team provides clear guidance on administration timing, which may be strategically aligned with your circadian rhythm and sleep schedule.
4
Sleep Quality Monitoring
Follow-up appointments assess changes in your sleep quality, duration, and daytime function. Your physician adjusts your DSIP protocol based on both subjective sleep reports and objective markers.
Frequently Asked Questions

DSIP FAQ

No. DSIP is a neuromodulatory peptide that appears to work by normalizing sleep-wake patterns rather than by inducing sedation. Research suggests it helps restore natural sleep architecture, particularly slow-wave delta sleep, without the grogginess, dependence risk, or suppressed REM sleep associated with conventional sedative-hypnotic medications.
While both are involved in sleep regulation, they work through different mechanisms. Melatonin primarily signals circadian timing (telling the body it's nighttime), while DSIP appears to directly influence sleep architecture and depth, particularly delta-wave activity. DSIP also interacts with stress hormone pathways, which melatonin does not directly address.
Delta sleep (Stage 3 NREM, or slow-wave sleep) is the deepest phase of sleep, characterized by high-amplitude, low-frequency delta brain waves. It is the stage most associated with physical recovery, growth hormone release, immune function, and memory consolidation. Many sleep complaints involve insufficient time in this critical stage.
DSIP has been studied for its effects on the HPA (stress) axis, and research suggests it may help modulate cortisol levels that, when elevated at night, commonly disrupt sleep. While it is not an anxiolytic, its stress-hormone modulating properties may be relevant for individuals whose sleep disruption has a stress or anxiety component.
Individual responses vary. Some patients report improvements in sleep quality within the first few administrations, while others notice gradual changes over several weeks. DSIP appears to work by restoring natural patterns rather than forcing acute sedation, so the timeline may reflect how disrupted one's baseline sleep architecture is.
Research and clinical reports suggest that DSIP generally does not produce the morning-after sedation commonly associated with sleeping pills. Because it works by supporting natural sleep stages rather than suppressing wakefulness, most patients report feeling more refreshed rather than groggy upon waking.
Yes. Aspire physicians often incorporate DSIP as one component of a comprehensive sleep optimization approach that may include circadian hygiene practices, stress management, and addressing underlying hormonal or metabolic contributors to poor sleep.
Yes. DSIP was first isolated from rabbit brain tissue in 1977 and has since been identified in the human hypothalamus, pituitary gland, and bloodstream. Endogenous DSIP levels fluctuate with circadian rhythms, with concentrations varying between waking and sleeping states.

DSIP has been studied in clinical settings since the late 1970s, with research conducted primarily at European institutions. While multiple clinical studies exist, larger-scale controlled trials would strengthen the evidence base. Its mechanism remains an active area of investigation.

Ready to explore DSIP?

Talk with an Aspire clinician about your goals and whether DSIP therapy may be appropriate for you.

Text Us Now
(407) 233-4006  ·  8014 Via Dellagio Way #104, Orlando, FL 32819
ASPIRE CLINIC LOCATIONS

Speak With Our Experts